Physician profile
James D Peyton
NPI 1881646073
$10,433.22
in general payments reported to CMS, 2019-2025
64 companies · $2,570 in 2025
The $2,570 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,922 · 2020: $670 · 2021: $144 · 2022: $667 · 2023: $1,703 · 2024: $1,757 · 2025: $2,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,849 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,849.29 |
| Education | $181.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $808.11 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $780.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $684.59 | 2019-2025 | Tagrisso, Lynparza, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $655.89 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Amgen INC. | $513.48 | 2019-2023 | Kyprolis, Nplate, Xgeva |
| Celgene Corporation | $393.50 | 2019-2025 | Reblozyl, Pomalyst |
| Regeneron Healthcare Solutions, INC. | $361.91 | 2022-2025 | Libtayo |
| Pfizer INC. | $322.67 | 2019-2025 | |
| Incyte Corporation | $316.51 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $297.20 | 2019-2025 | Tecentriq, Polivy, Tecentriq Hybreza |
| Janssen Biotech, INC. | $284.25 | 2019-2025 | Talvey, Tecvayli, Darzalex |
| Abbvie INC. | $273.62 | 2020-2025 | |
| Seagen INC. | $249.96 | 2020-2023 | Adcetris, Tukysa, Padcev |
| Genzyme Corporation | $241.02 | 2019-2025 | |
| Daiichi Sankyo INC. | $236.60 | 2019-2025 | Enhertu, Injectafer |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Peyton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.